Cutaneous T-cell lymphomas.
Cutaneous T-cell lymphoma, which usually presents as mycosis fungoides or Sézary syndrome, remains a mostly incurable, yet highly treatable group of diseases. The myriad of active therapies continues to grow, and new insights into the mechanism of systemic and topical therapies are being elucidated. Multimodality treatment initiated for early-stage disease may help improve long-term survival. The need for randomized prospective trials is obvious and should become a priority. Further development of molecular genetic techniques and cell-surface phenotyping has enhanced our understanding of these diseases and will hopefully allow for the development of more effective and specific treatments.
Kaplan
E H
EH
Rush University, Section of Medical Oncology, Chicago, IL 60612.
Leslie
W T
WT
D006801:Humans; D007150:Immunohistochemistry; D007372:Interferons / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D017893:Photopheresis; D014467:Ultraviolet Therapy
D007372:Interferons